ESG Report 2019

16 PRODUCT LABELLING AND DESCRIPTION The Group has formulated and implemented improper transportation and storage. Besides, relevant management systems for label package inserts must contain details of the packaging materials in accordance with laws pharmaceutical's directions, data and and regulations. All package inserts and information showing its safety, effectiveness labels comply with the requirements in the and adverse drug reactions, so as to guide P r o v i s i on s on t he Adm i n i s t r a t i on o f users to take the pharmaceuticals correctly Pharmaceutical Directions and Labels and are and reasonably. The Group will constantly subject to examination, filing and approval by monitor the use of the pharmaceuticals, and the National Medical Products Administration. will submit applications to the National Medical Products Administration to amend package inserts when necessary, so as to The Group has formulated internal policies, provide users with the best pharmaceutical stipulating that pharmaceutical labels and information and description. package inserts must meet relevant requirements. Pharmaceutical labels must At the same time, the Group has also set up itemize the drug name, ingredients, use of management procedures for plate making, drug, directions and dosage, production date printing, and acceptance of product labels, and other relevant information to let users manuals, and printed packaging materials. understand the usage and risks of the The Quality Management Department will pharmaceuticals. Apart from pharmaceutical carry out acceptance and inspection work at l a b e l s , t h e G r o u p a l s o f o r mu l a t e s every step, from the drafting, sample printing requirements for packaging labels on to printing of product labels, manuals and transportation, storage use and active packaging materials. This ensures that all the pharmaceutical ingredients. For example, materials will be put into the factories for use such packaging labels must indicate the without errors, and minimizes the possibility of pharmaceutical name, number of packages, product quality problems caused by printing expiration date, storage and transportation errors. precautions and other necessary information to avoid incidents affecting drug quality due to On March 22, 2019, Mr. Defu Liu, the Quality Director of The United Laboratories, presided over the special t r a i n i n g o n “ P h a r m a c e u t i c a l Regulations are the Root and Top of the Sustained Health of Pharmaceutical Manufacturers”. Nearly 300 people from various departments such as q u a l i t y m a n a g e m e n t s y s t e m , production plants, engineering and equipment department participated in the training. Director Liu gave detailed explanation on the relationship between pharma- ceutical laws and pharmaceutical production. ACTIVITY LOG His explanation covered five aspects, including changes on processes, consistency evaluation, associated review and the system of the holders of drug marketing licenses, with particular emphasis on process changes. He analyzed the possibility of modification, current regulations, supplementary applications, pending approval, equivalence research, etc. item by item, and imparted relevant experience of the National Medical Products Administration's diversified policies, rational use of resources, and consistency of document content and requirements to employees under training. Environmental, Social and Governance Report 2019 The United Laboratories International Holdings Limited